Actively Recruiting

Phase 1
Age: 18Years - 100Years
MALE
NCT07174063

A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

Led by Novartis Pharmaceuticals · Updated on 2026-04-28

15

Participants Needed

4

Research Sites

83 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This Phase I study aims to evaluate the safety, tolerability and PK of JSB462 in Japanese patients with metastatic prostate cancer.

CONDITIONS

Official Title

A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

Who Can Participate

Age: 18Years - 100Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male adults with confirmed adenocarcinoma of the prostate
  • Presence of at least one bone or visceral metastatic lesion on recent imaging within 28 days before enrollment
  • Failed or refused standard therapies for prostate cancer, or ineligible or intolerant to such therapies
  • Castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L); ongoing androgen deprivation therapy allowed
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Not Eligible

You will not qualify if you...

  • Presence of central nervous system (CNS) metastases
  • Any active malignancy other than prostate cancer, except for certain treated cancers with no recurrence for at least 3 years or specific skin cancers treated curatively
  • Other exclusion criteria may apply

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Novartis Investigative Site

Nagoya, Aichi-ken, Japan, 4668560

Active, Not Recruiting

2

Novartis Investigative Site

Bunkyo Ku, Tokyo, Japan, 1138677

Actively Recruiting

3

Novartis Investigative Site

Koto Ku, Tokyo, Japan, 1358550

Actively Recruiting

4

Novartis Investigative Site

Kobe, Japan, 650-0017

Active, Not Recruiting

Loading map...

Research Team

N

Novartis Pharmaceuticals

CONTACT

N

Novartis Pharmaceuticals, +41613241111

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here